Who are Amlodipine plus Metformin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-plus-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Amlodipine plus Metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amlodipine plus Metformin (Amlodipine plus Metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: calcium channel blocker + biguanide antidiabetic. Area: Cardiovascular and Endocrinology.

marketed Combination therapy: calcium channel blocker + biguanide antidiabetic L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin) Cardiovascular and Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine plus Metformin (Amlodipine plus Metformin) — Third Military Medical University. This combination reduces blood pressure through calcium channel blockade (amlodipine) while improving glucose control through enhanced insulin sensitivity and reduced hepatic glucose production (metformin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amlodipine plus Metformin TARGET	Amlodipine plus Metformin	Third Military Medical University	marketed	Combination therapy: calcium channel blocker + biguanide antidiabetic	L-type voltage-gated calcium channels (amlodipine); AMP-activated protein kinase and mitochondrial glycerophosphate dehydrogenase (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: calcium channel blocker + biguanide antidiabetic class)

Third Military Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine plus Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-plus-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab